Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Malignant Solid Tumor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,056 result(s) found for: Malignant Solid Tumor. Displaying page 24 of 53.
    «« First « Previous 20  21  22  23  24  25  26  27  28  Next» Last»»
    EudraCT Number: 2011-000642-37 Sponsor Protocol Number: AZD4547-2011 Start Date*: 2011-11-08
    Sponsor Name:Greater Glasgow Health Board [...]
    1. Greater Glasgow Health Board
    2. University of Glasgow
    Full Title: A Phase I/IIa trial of AZD4547 in combination with Cisplatin and Capecitabine (CX)
    Medical condition: Stage 1 - Patients with advanced solid tumours. Stage 2 - Histologically proven adenocarcinoma or undifferentiated carcinoma of the oesophagus, gastro-oesophageal junction, or stomach.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065147 Malignant solid tumor LLT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030139 Oesophageal adenocarcinoma NOS LLT
    16.0 10022891 - Investigations 10060139 Antineutrophil cytoplasmic antibody decreased PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001150 Adenocarcinoma gastric PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004936-72 Sponsor Protocol Number: WO42178 Start Date*: 2021-08-25
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, OPEN-LABEL, MULTICENTER, PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF BIOMARKER-DRIVEN THERAPIES IN PATIENTS WITH PERSISTENT OR RECURRENT RARE EPITHELIAL OVARIAN TUMORS
    Medical condition: Persistent or Recurrent Rare Epithelial Ovarian Tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033129 Ovarian neoplasms malignant (excl germ cell) HLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026669 Malignant peritoneal neoplasm NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033159 Ovarian epithelial cancer NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) BE (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022163-35 Sponsor Protocol Number: EFC11785 Start Date*: 2011-04-04
    Sponsor Name:sanofi-aventis R&D
    Full Title: Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination with Prednisone for the Treatment of Metastatic Castration Resistant Prostat...
    Medical condition: metastatic Castration Resistant Prostate Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) HU (Completed) BE (Completed) ES (Completed) GB (Completed) FR (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-024298-37 Sponsor Protocol Number: ESOT/1/2010 Start Date*: 2011-03-28
    Sponsor Name:Dipartimento Integrato di Oncologia, Ematologia e Patologie dell'Apparato Respiratorio
    Full Title: Early strong opiod treatment in cancer pain -Morphine vs weak opiods
    Medical condition: Tumor Pain, mild-moderate intensity (VAS 3-7)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000995-14 Sponsor Protocol Number: MIV-818-101/201 Start Date*: 2018-08-10
    Sponsor Name:Medivir AB
    Full Title: A Phase 1/2a Study in 3 Parts (Phase 1a and Phase 1b - Dose Escalations and Phase 2a Expansion Cohorts) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of...
    Medical condition: hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), or, metastatic liver disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073077 Intrahepatic cholangiocarcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027479 Metastatic liver carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001755-31 Sponsor Protocol Number: NCT-2017-0417 Start Date*: 2018-08-31
    Sponsor Name:Ruprecht-Karls-Universität Heidelberg, Medical Faculty
    Full Title: Randomized Phase-II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies
    Medical condition: Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000137-17 Sponsor Protocol Number: BA3021-001 Start Date*: 2022-09-27
    Sponsor Name:BioAtla
    Full Title: A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozuriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors
    Medical condition: Advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) GR (Completed) IT (Prematurely Ended) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003742-36 Sponsor Protocol Number: MK-3475-02D Start Date*: 2021-02-16
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc
    Full Title: A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D
    Medical condition: Melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) GR (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001551-13 Sponsor Protocol Number: D0818C00001 Start Date*: 2013-08-21
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following ...
    Medical condition: BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002483-27 Sponsor Protocol Number: PKB116611 Start Date*: 2012-11-07
    Sponsor Name:Accenture
    Full Title: An Open-Label Phase I/II Study of GSK2110183 in Combination with Carboplatin and Paclitaxel in Subjects with Platinum-Resistant Ovarian Cancer
    Medical condition: Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-001211-33 Sponsor Protocol Number: EFC10339 Start Date*: 2007-06-20
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: International randomized study to evaluate the addition of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) vs. cisplatin-5-fluorouracil (CF) in the induction treatment of nasopharyng...
    Medical condition: Children and adolescents newly diagnosed with NPC with measurable disease T2-T4 any NM, of <18 years of age at the time of diagnosis. ---------- Niños y adolescentes recien diagnosticados con CNF c...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028793 Nasopharyngeal carcinoma LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) GR (Prematurely Ended) FR (Completed) IT (Completed) DE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-005875-17 Sponsor Protocol Number: CMEK162X2110 Start Date*: 2012-05-30
    Sponsor Name:Array Biopharma Inc
    Full Title: A Phase Ib/II, multicenter, open-label, dose escalation study of LGX818 in combination with MEK162 in adult patients with BRAF V600 - dependent advanced solid tumors
    Medical condition: Patients with solid tumors harboring a BRAF V600 mutation.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) BE (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2006-002316-10 Sponsor Protocol Number: H6Q-MC-S019(b) Start Date*: 2006-10-09
    Sponsor Name:Eli Lilly and Company limited
    Full Title: A Randomized, Phase 2, Placebo-Controlled, Double-Blinded Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin as First-Line Treatment, Followed by Maintenance Treatmen...
    Medical condition: Patients with a histologic diagnosis of FIGO Stage IIB, IIC, III, or IV advanced invasive epithelial ovarian, fallopian tube, or peritoneal carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-006134-17 Sponsor Protocol Number: IPM3002 Start Date*: 2012-07-30
    Sponsor Name:ZIOPHARM Oncology, Inc.
    Full Title: A Multi-center, Open-Label, Adaptive, Randomized Study of Palifosfamide-tris, a Novel DNA Crosslinker, in Combination with Carboplatin and Etoposide (PaCE) Chemotherapy versus Carboplatin and Etopo...
    Medical condition: Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) PL (Completed) IT (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-002444-32 Sponsor Protocol Number: 17-122 Start Date*: 2017-12-18
    Sponsor Name:CHU CAEN
    Full Title: Maintenance Brentuximab Vedotin (Bv) Following Allogeneic Stem Cell Transplantation for Hodgkin Lymphoma Patient: A Prospective, Multicenter, Phase II Study
    Medical condition: Hodgkin Lymphoma Patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002771-25 Sponsor Protocol Number: NSABP_B-59/GBG96 Start Date*: 2018-04-03
    Sponsor Name:NSABP Foundation Inc.
    Full Title: A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of At...
    Medical condition: Patients with early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001220-30 Sponsor Protocol Number: EGF117165 Start Date*: 2014-07-25
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: An Open-Label, Phase II, Study to Evaluate Biomarkers Associated with Response to Subsequent Therapies in Subjects with HER2-Positive Metastatic Breast Cancer Receiving Treatment with Trastuzumab i...
    Medical condition: HER2 positive Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended) IT (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004083-21 Sponsor Protocol Number: E7438-G000-101 Start Date*: 2015-02-02
    Sponsor Name:Epizyme, Inc.
    Full Title: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas
    Medical condition: Relapsed or refractory Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Advanced solid tumor
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004246-11 Sponsor Protocol Number: EDO-S101-1002 Start Date*: 2021-09-30
    Sponsor Name:Mundipharma Research Limited
    Full Title: A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients with Ad...
    Medical condition: • Cohort 1: Relapsed/refractory Small Cell Lung Cancer • Cohort 2: Relapsed/refractory Soft Tissue Sarcoma • Cohort 3: Relapsed/refractory Triple-Negative Breast Cancer • Cohort 4: Relapsed/refr...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10041071 Small cell lung cancer stage unspecified LLT
    23.0 100000004864 10084066 Triple negative breast cancer metastatic LLT
    20.0 100000004864 10033130 Ovarian cancer NOS LLT
    21.0 100000004864 10014735 Endometrial cancer NOS LLT
    20.0 100000004864 10002479 Angiosarcoma NOS LLT
    21.1 100000004864 10057043 Dermatofibrosarcoma LLT
    21.1 100000004864 10015103 Epithelioid sarcoma NOS LLT
    20.0 100000004864 10024193 Leiomyosarcoma NOS LLT
    20.0 100000004864 10024631 Liposarcoma NOS LLT
    22.1 100000004864 10082807 Solitary fibrous tumor LLT
    20.0 100000004864 10042866 Synovial sarcoma NOS LLT
    21.1 100000004864 10025556 Malignant fibrous histiocytoma NOS LLT
    20.0 100000004864 10029276 Neurofibrosarcoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002337-19 Sponsor Protocol Number: STUDIODH-OMEOPATIA Start Date*: 2011-09-05
    Sponsor Name:AZIENDA UNITA' SANITARIA LOCALE DI PARMA
    Full Title: A PHASE II EXPLORATIVE STUDY EVALUATING ACTIVITY AND SAFETY OF HOMEOPATHIC MEDICINE ON CANCER RELATED FATIGUE (CRF) AND QUALITY OF LIFE IN ONCOLOGIC PATIENTS UNDER CHEMOTHERAPY IN DAY HOSPITAL AT ...
    Medical condition: Oncologic patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 20  21  22  23  24  25  26  27  28  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 24 02:11:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA